GM-1020 is under clinical development by Gilgamesh Pharmaceuticals and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GM-1020’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GM-1020 overview

GM-1020 is under development for the treatment of major depressive disorder and opiate use disorder. It is an arylcyclohexylamine, that acts by targeting NMDA receptor. The drug candidate is administered through oral route.

Gilgamesh Pharmaceuticals overview

Gilgamesh is a serious mental health science focused, preclinical biotechnology company. The company has a disciplined focus on developing innovative new chemical entities (NCE’s) leveraging a combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise.

For a complete picture of GM-1020’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.